Biogen Price Target Maintained With a $292.00/Share by RBC Capital
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $292 Price Target
Biogen Analyst Ratings
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260
Optimistic Buy Rating for Biogen on Strategic Cost-Cutting and Growth Asset Prioritization
Biogen Price Target Maintained With a $285.00/Share by Needham
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $285
Biogen Analyst Ratings
Biogen's Upward Trajectory: A Buy Rating on Alzheimer's and Pipeline Progress
Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $270
Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB)
Needham Reiterates Buy on Biogen, Maintains $285 Price Target
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $285
Biogen Analyst Ratings
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $251